What is HC Wainwright’s Forecast for RenovoRx Q2 Earnings?

RenovoRx, Inc. (NASDAQ:RNXT) – Equities research analysts at HC Wainwright increased their Q2 2026 earnings per share estimates for shares of RenovoRx in a research note issued on Friday, May 15th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.08) per share for the quarter, up from their previous forecast of ($0.09). HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for RenovoRx’s current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for RenovoRx’s Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.33) EPS, Q1 2027 earnings at ($0.03) EPS, Q2 2027 earnings at ($0.02) EPS, Q3 2027 earnings at $0.00 EPS, Q4 2027 earnings at $0.01 EPS, FY2027 earnings at ($0.02) EPS and FY2028 earnings at $0.20 EPS.

Other research analysts have also issued research reports about the company. Ascendiant Capital Markets lifted their target price on RenovoRx from $13.00 to $13.50 and gave the stock a “buy” rating in a research report on Thursday, April 9th. Wall Street Zen lowered RenovoRx from a “hold” rating to a “strong sell” rating in a research report on Saturday, April 4th. Finally, JonesTrading upgraded RenovoRx to a “strong-buy” rating in a research report on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $8.25.

RenovoRx Trading Down 4.5%

Shares of RNXT opened at $0.78 on Tuesday. The firm has a market cap of $35.29 million, a price-to-earnings ratio of -2.37 and a beta of 1.00. The stock has a 50 day moving average of $0.94 and a 200-day moving average of $0.94. RenovoRx has a 52 week low of $0.70 and a 52 week high of $1.45.

RenovoRx (NASDAQ:RNXT) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). The company had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.47 million. RenovoRx had a negative return on equity of 135.03% and a negative net margin of 823.98%.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in RNXT. AIGH Capital Management LLC boosted its position in RenovoRx by 30.8% during the 1st quarter. AIGH Capital Management LLC now owns 3,706,197 shares of the company’s stock valued at $3,682,000 after purchasing an additional 872,303 shares during the period. Wealthspire Advisors LLC acquired a new position in RenovoRx during the 4th quarter valued at approximately $212,000. Citadel Advisors LLC acquired a new position in RenovoRx during the 3rd quarter valued at approximately $154,000. Northwestern Mutual Wealth Management Co. acquired a new position in RenovoRx during the 2nd quarter valued at approximately $98,000. Finally, Bleichroeder LP boosted its position in RenovoRx by 11.4% during the 4th quarter. Bleichroeder LP now owns 600,000 shares of the company’s stock valued at $504,000 after purchasing an additional 61,379 shares during the period. Institutional investors and hedge funds own 3.10% of the company’s stock.

About RenovoRx

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.